{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:25:51Z","timestamp":1781454351954,"version":"3.54.1"},"reference-count":43,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To describe infusion reactions (IR) and severe adverse events (SAE) associated with infliximab (IFX) in pediatric patients with rheumatologic and ocular inflammatory diseases in a real-world setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>This is a retrospective chart review of all patients treated with IFX at the pediatric rheumatology division of a university hospital between October 2000 and December 2012.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>A total of 2446 IFX infusions were given to 82 patients (72% female). IR occurred in 46 infusions (2%) of 14 patients (17%) after a mean IFX treatment time of 340 days (range 41\u2013780); 9\/14 patients (64%) experienced repeated IR. IR were classified as mild (26%), moderate (74%), or severe (0%). Indications for IFX were arthritis (60%), uveitis (20%), arthritis and uveitis (13%), and other inflammatory diseases (5%). The most common clinical symptoms were respiratory signs (72%), cutaneous manifestations (69%), and malaise (61%). In 6\/14 patients (43%) with IR, IFX was discontinued: 4 patients because of repeated IR and 2 patients wished to stop treatment immediately following a mild IR. The other 8\/14 patients (57%) received premedication with high-dose antihistamine (100%), corticosteroids (75%), and IFX dose increase (75%) and continued IFX treatment for a mean followup period of 146 weeks (range 26\u2013537) after the first IR. We observed severe infections in 5\/82 patients (6%); other SAE were rare.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Mild and moderate IR occurred in 17% of our patients. Treatment with antihistamines and methylprednisolone, and increasing the IFX dose, allowed continued treatment despite IR in &gt; 50% of patients. Other SAE were infrequent.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.131231","type":"journal-article","created":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T05:03:59Z","timestamp":1400216639000},"page":"1409-1415","source":"Crossref","is-referenced-by-count":17,"title":["Infliximab in Pediatric Rheumatology Patients: A Retrospective Analysis of Infusion Reactions and Severe Adverse Events During 2246 Infusions over 12 Years"],"prefix":"10.3899","volume":"41","author":[{"given":"Florence A.","family":"Aeschlimann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Cannizzaro Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Lauener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rotraud K.","family":"Saurenmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2014,5,15]]},"reference":[{"key":"2018112909331141000_41.7.1409.1","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1542\/peds.90.6.950","article-title":"Epidemiology of juvenile chronic arthritis in southwestern Sweden: a 5-year prospective population study","volume":"90","author":"Gare","year":"1992","journal-title":"Pediatrics"},{"key":"2018112909331141000_41.7.1409.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780291008"},{"key":"2018112909331141000_41.7.1409.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.06.014"},{"key":"2018112909331141000_41.7.1409.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.05.002"},{"key":"2018112909331141000_41.7.1409.5","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2004.050609"},{"key":"2018112909331141000_41.7.1409.6","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20460"},{"key":"2018112909331141000_41.7.1409.7","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.124081"},{"key":"2018112909331141000_41.7.1409.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.01.005"},{"key":"2018112909331141000_41.7.1409.9","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.4"},{"key":"2018112909331141000_41.7.1409.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110956"},{"key":"2018112909331141000_41.7.1409.11","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21641"},{"key":"2018112909331141000_41.7.1409.12","first-page":"18","article-title":"Maintenance and tolerability of infliximab in a cohort of 152 patients with rheumatoid arthritis","volume":"26","author":"Figueiredo","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909331141000_41.7.1409.13","first-page":"1912","article-title":"Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number","volume":"31","author":"Wasserman","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909331141000_41.7.1409.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07457.x"},{"key":"2018112909331141000_41.7.1409.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.21671"},{"key":"2018112909331141000_41.7.1409.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020888"},{"key":"2018112909331141000_41.7.1409.17","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W"},{"key":"2018112909331141000_41.7.1409.18","doi-asserted-by":"publisher","DOI":"10.1203\/PDR.0b013e318208451d"},{"key":"2018112909331141000_41.7.1409.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.10.021"},{"key":"2018112909331141000_41.7.1409.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.22838"},{"key":"2018112909331141000_41.7.1409.21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120583"},{"key":"2018112909331141000_41.7.1409.22","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20246"},{"key":"2018112909331141000_41.7.1409.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.20793"},{"key":"2018112909331141000_41.7.1409.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087130"},{"key":"2018112909331141000_41.7.1409.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.100354"},{"key":"2018112909331141000_41.7.1409.26","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909331141000_41.7.1409.27","first-page":"1991","article-title":"Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997","volume":"25","author":"Petty","year":"1998","journal-title":"J Rheumatol"},{"key":"2018112909331141000_41.7.1409.28","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057406"},{"key":"2018112909331141000_41.7.1409.29","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.099978"},{"key":"2018112909331141000_41.7.1409.30","first-page":"50","article-title":"[Long-term evaluation of infliximab in the treatment of persistently active juvenile idiopathic arthritis refractory to conventional therapy]","volume":"59","author":"De Marco","year":"2007","journal-title":"Reumatismo"},{"key":"2018112909331141000_41.7.1409.31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1155\/2010\/138456","article-title":"The safety of infliximab infusions in the community setting","volume":"24","author":"Ducharme","year":"2010","journal-title":"Can J Gastroenterol"},{"key":"2018112909331141000_41.7.1409.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.03.006"},{"key":"2018112909331141000_41.7.1409.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2007.00042.x"},{"key":"2018112909331141000_41.7.1409.34","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.12"},{"key":"2018112909331141000_41.7.1409.35","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.070771"},{"key":"2018112909331141000_41.7.1409.36","doi-asserted-by":"publisher","DOI":"10.1002\/art.22214"},{"key":"2018112909331141000_41.7.1409.37","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker124"},{"key":"2018112909331141000_41.7.1409.38","doi-asserted-by":"publisher","DOI":"10.1002\/art.10302"},{"key":"2018112909331141000_41.7.1409.39","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130133"},{"key":"2018112909331141000_41.7.1409.40","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283521c4e"},{"key":"2018112909331141000_41.7.1409.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.04.003"},{"key":"2018112909331141000_41.7.1409.42","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3182a702e8"},{"key":"2018112909331141000_41.7.1409.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.10.007"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.131231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T17:40:56Z","timestamp":1649007656000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.131231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,15]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7,1]]},"published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.3899\/jrheum.131231"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.131231","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,15]]}}}